-
Views
-
Cite
Cite
Kelley A. Gordon, Michael A. Pfaller, Ronald N. Jones, the SENTRY Participants Group, BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10 000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000), Journal of Antimicrobial Chemotherapy, Volume 49, Issue 5, May 2002, Pages 851–855, https://doi.org/10.1093/jac/dkf028
Close - Share Icon Share
Abstract
BMS284756 is a novel des-F (6)-quinolone, which has a wide range of activity against many species of Gram-positive and -negative organisms. The potency of BMS284756 was compared with that of other quinolones, including ciprofloxacin, gatifloxacin and levofloxacin, and was tested against >10 000 bloodstream isolates from the year 2000 SENTRY antimicrobial surveillance programme. Twelve pathogens accounted for nearly all of the referred isolates and included Staphylococcus aureus, coagulase-negative staphylococci, Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Serratia spp., Pseudomonas aeruginosa, Acinetobacter spp., Enterococcus spp., Streptococcus pneumoniae and β-haemolytic or viridans group streptococci. Of the four quinolones tested, BMS284756 was the most active overall against Staphylococcus spp. (MIC50 ≤ 0.03 mg/L) and Streptococcus spp. (MIC50 0.06 mg/L). In contrast, BMS284756 was less potent than the other quinolones against the enteric Gram-negative bacilli (MIC50 ≤ 0.03–1 mg/L). With a proposed breakpoint of ≤4 mg/L, BMS284756 may be a therapeutic alternative pending the results of clinical trials.
